Rhabdomyolysis from the Combination of a Statin and Gemfibrozil: An Uncommon But Serious Adverse Reaction
|
|
- Ashlie Chase
- 6 years ago
- Views:
Transcription
1 Rhabdomyolysis from the Combination of a Statin and Gemfibrozil: An Uncommon But Serious Adverse Reaction Amy Haavisto Kind, MD; Laura J. Zakowski, MD; Patrick E. McBride, MD ABSTRACT We report a patient with renal insufficiency who developed rhabdomyolysis 1 month after initiating cerivastatin and gemfibrozil for hyperlipidemia. Myopathy caused by HMG-CoA reductase inhibitors (statins) alone is rare, but occurs more frequently when a statin is used with gemfibrozil, a medication that likely has a direct toxic effect on muscles. Predisposing factors to the development of myopathy from the combination include use of medications affecting statin metabolism, higher doses of statins, renal insufficiency, diuretics, and hypothyroidism. It has been proposed that alternate-day therapy with a statin and fibrate, spacing of doses in a single day, or use of lower doses of statins may prevent the development of myopathy. Currently, no predictable method to determine who is at risk for myopathy exists, nor is there a reliable screening test. Therefore, patients should be advised to watch for generalized muscle pain or weakness, and if it occurs, stop medications and report symptoms immediately. Doctor Kind is a second year internal medicine resident at Massachusetts General Hospital. She graduated from the University of Wisconsin Medical School in May Doctor Zakowski is assistant professor of medicine at the University of Wisconsin Medical School. She is a general internist practicing in Madison and co-directs Patient, Doctor and Society, a course that teaches first and second year medical students history and physical examination. Doctor McBride is professor of medicine (cardiovascular) and family medicine. He is the director of Preventive Cardiology at the University of Wisconsin Medical School and UW Hospital and Clinics. Address reprint requests to Laura Zakowski, MD, 326 Bradley Memorial, 1300 University Ave; Madison, WI 53706; zakowski@facstaff.wisc.edu.... INTRODUCTION The Third Adult Treatment Panel Guidelines of the National Cholesterol Education Program released in May 2001 (NCEP ATP III) encourage more aggressive treatment of elevated triglycerides and low highdensity lipoprotein (HDL) than previous guidelines, while continuing to emphasize the importance of treating elevated low-density lipoprotein (LDL) levels. 1 Statins lower LDL levels very effectively, while gemfibrozil and other fibrates lower triglycerides and raise HDL more effectively. The combination of the two medications, often useful for patients with a combined hyperlipidemia, increases the risk of myopathy (muscle pain or weakness with an elevated creatine kinase [CPK] of at least 10 times normal) and rhabdomyolysis (rapid and severe muscle breakdown with its associated metabolic effects). CASE PRESENTATION A 51-year-old female with a history of hypertension, hypercholesterolemia, peripheral arterial disease and renal insufficiency (baseline creatinine 1.6) presented to the emergency room with progressive muscle pain, weakness, and lethargy. Initially she noted diffuse arm and leg pain 2 weeks earlier, but attributed her pain to peeling numerous bags of potatoes the previous day. Medications at time of presentation included naproxen, cyclobenzaprine, amlodipine/ benazepril, metoprolol, cerivastatin and gemfibrozil. Her physician had initiated both cerivastatin and gemfibrozil 1 month earlier for treatment of elevated LDL and triglycerides. She denied recent trauma, excessive exercise, infection, seizure, or ethanol use. Physical exam revealed a moderately obese woman who appeared alert, but acutely ill. Vital signs were significant for an elevated systolic blood pressure (170/70). Diffuse tenderness to palpation was noted along her arms and legs with normal strength and sensation. The remainder of the physical exam was unremarkable. Initial laboratory data were remarkable for a potassium of 8.5 mmol/l (normal, ), creatinine of 8.0 mg/dl (normal, ), blood urea nitro- 53
2 gen of 136 mg/dl (normal, 7-20), and CPK of 22,770 U/L (normal, 0-250). Urine myoglobin was negative. Electrocardiogram exhibited changes consistent with hyperkalemia, including PR lengthening, QRS prolongation and peaked T waves. She was diagnosed with acute renal failure and rhabdomyolysis. This was likely due to the initiation of both a statin and gemfibrozil in the setting of renal insufficiency while taking amlodipine, a medication that causes increased statin levels. In addition to traditional emergent treatment for hyperkalemia, she required 1 course of dialysis for persistent hyperkalemia. Her rhabdomyolysis was treated with intravenous fluids, mannitol, and urine alkalinization. Over the 7 days of her hospitalization, her CPK and creatinine declined gradually, and she was discharged with a creatinine of 2.5. One month later creatinine was back to her baseline at 1.3. DISCUSSION Rhabdomyolysis, a severe myopathy caused by injury of skeletal muscle, results in release of cellular contents into the circulation. Rhabdomyolysis can lead to severe metabolic abnormalities (hyperkalemia, hyperphosphatemia, hypocalcemia, hyperuricemia, and hypoalbuminemia), disseminated intravascular coagulation, and acute renal failure. The differential diagnosis of rhabdomyolysis includes massive trauma (crush injuries), hypothermia, hyperpyrexic syndromes, infections, hypoxia, metabolic disorders, immunologic disease (dermatomyositis/polymyositis), and toxins (ethanol, cocaine, PCP, and amphetamines). Statins rarely cause myopathy, but it is more common when patients take medications that inhibit or interfere with cytochrome P450 enzymes. 2 The use of other medications may lead to large increases in the plasma concentrations of statins, since most statins are at least partly metabolized by this cytochrome. Muscle tissue might be sensitive to elevated blood levels of statins, 3 leading to a myopathy in the presence of a competing medication. The list of medications inhibiting this isoenzyme is long and documented in the table. Each medication may have a variable effect on the blood level of the statin. One study showed that itraconazole can cause a 19-fold increase in the serum level of simvastatin. 4 Grapefruit and grapefruit juice are also potent inhibitors of the cytochrome P450-3A4 isoenzyme, thus patients taking statins should limit grapefruit intake. 5 A modest amount of grapefruit ingestion... Table 1. Drugs that inhibit or are metabolized by the cytochrome P450 isoenzymes* Over-the-counter acetominophen Antibiotics clarithromycin erythromycin norfloxacin Antifungals clotrimazole fluconazole itraconazole ketoconazole miconazole Antidepressants fluoxetine fluvoxamine nefazodone imipramine sertraline Food grapefruit Cardiovascular amiodarone amlodipine digoxin diltiazem felodipine isradipine losartan mibefradil nifedipine quinidine verapamil Miscellaneous CNS alprazolam carbamezapine midazolam phenobarbital phenytoin triazolam Protease inhibitors indinavir ritonavir nelfinavir saquinavir Other cimetidine cyclosporine danazole dexamethasone ergotamine ethinyl estradiol omeprazole propoxyphene rifampin sildenafil tacrolimus theophylline zafirlukast * Adapted from Cheitlin MD, Hutter AM, Brindis RG, et al. Circulation 1999;99: (up to 1 quart of juice a day) with statins is not problematic, 7 especially if the grapefruit is ingested in the morning and the statin is taken in the evening. This problem does not apply to other citrus fruits or other foods in general. The potential interaction of each statin with other medications may differ depending on which isoenzyme it is metabolized by, and the degree with which it is metabolized. Lovastatin, simvastatin and atorvastatin are metabolized exclusively through the 3A4 isoenzyme. Cerivastatin is metabolized through both the 3A4 and 2C8 isoenzymes, and fluvastatin is metabolized through the 2C9 isoenzyme. Studies directly comparing toxicities across statins are lacking, but pravastatin should be safest when prescribing other medications affecting liver metabolism, since it is not significantly metabolized through cytochromes. 2 Myopathy can occur with either statin or fibrate monotherapy. One study reported an incidence of 0.08% in patients taking simvastatin 7 and another reported the same percent for lovastatin. 8 In a population-based cohort, the frequency of myopathy in patients taking statins was 1.2 per 10,000 personyears. 9 The fibrate class of drugs, including gemfibrozil can also cause myopathy, but the mechanism 54
3 ... is unknown. 10 It has been proposed that gemfibrozil may have a direct toxic effect on the muscles, 11 similar to the myositis described by a related fibrate, clofibrate. 12 Fibrates are excreted by the kidney, and the risk of myopathy increases in patients with renal insufficiency. 2 The degree of increase in this risk is not known. In the same population-based cohort reported above, the frequency of myopathy from fibrates was 6.6 per 10,000 person-years. 9 Often, statin therapy alone only partially treats the lipid abnormality in patients with combined dyslipidemias. If a patient does not have adequate triglyceride control when already on an agent to lower LDL, the choices include niacin, fish oil capsules or fibrates (gemfibrozil or fenofibrate). A number of studies examining the efficacy and safety of a statin and gemfibrozil used together demonstrate that this combination approach is more effective than monotherapy at reducing lipid levels and, for the most part, is quite safe. 13,14 The risk of myopathy with combination statin and gemfibrozil therapy ranges from 0.4% up to 5.0% of patients taking the medication over the course of a study, the latter with lovastatin. 13,15 The frequency of this occurrence has not been reported for cerivastatin, but is higher than the other statin-gemfibrozil combinations. 1 In one study, myalgias without CK elevation were found to be the most common reason for discontinuation of combination therapy, occurring in 2% of subjects. 13 The other medications that can be used with statins to treat elevated triglycerides have not been as well-studied as gemfibrozil. The incidence of myositis from the combination of a statin and fenofibrate is not currently well-documented, but a study evaluating the combination of fluvastatin and fenofibrate documented no significant increase in CPK levels. 16 Two prospective studies showed no increase in adverse effects when a statin and niacin were used together. 17,18 There are no reported cases of myopathy occurring from the combination of a statin and fish oil. 19 Several case studies of gemfibrozil-statin related rhabdomyolysis have been reported in the medical literature. This life-threatening complication has been reported with lovastatin, simvastatin, cerivastatin, and atorvastatin. 3,20-22 If CPK measurements were obtained prior to the reported episodes, these were normal, suggesting that screening CPK levels may be of low utility. Predisposing factors to development of myopathy when the combination is used has not been well-studied. Published reports suggest that hypothyroidism, 23 diuretic therapy, 11 high doses of statins, and renal insufficiency 10 are important factors. In one case dehydration and pancreatitis was thought to be the cause. 22 Because of a higher incidence of myopathy when combined with gemfibrozil, cerivastatin was withdrawn from the market. Lovastatin also has a relatively high incidence of myopathy when combined with gemfibrozil, and it should be used with caution. It is likely lovastatin use will increase, since it will soon be available in generic form. The gemfibrozil label itself states that the benefit of combination therapy with a statin and gemfibrozil does not outweigh the risks of severe myopathy, rhabdomyolysis and acute renal failure. 24 The combination of a statin and gemfibrozil is often needed, however, for severe combined dyslipidemias, and this has been approved by the new NCEP ATP III guidelines. 1 To avoid complications with use of a statin and gemfibrozil, administration of simvastatin on alternate days with fenofibrate has been effective in lowering lipid levels with very few side effects. 25 Administration of a fibrate in the morning and a statin in the evening may also be a safe alternative 10,19 because both medications have a short half-life, and one would be mostly cleared from the circulation before the administration of the other. Others have advocated prescribing lower doses of statins with fibrates to minimize complications. 2 Temporarily discontinuing lipid-lowering therapy may be a useful preventive strategy if a condition occurs that places a patient at increased risk of myopathy, such as major surgery, severe infection, hypotension, severe metabolic, electrolyte, or endocrine disorders or major trauma. 3 The University of Wisconsin Preventive Cardiology clinic uses the following treatment algorithm: 1) If a patient has very high triglyceride levels (>300 mg/dl) with a modest LDL elevation, niacin or gemfibrozil is used to lower the triglycerides to the target level. Because fenofibrate is more expensive than gemfibrozil, it is used only if patients have difficulty with either niacin or gemfibrozil. If the LDL is not lowered sufficiently with this treatment, then a low-dose statin is added. 2) If the patient has very high triglyceride levels (>300 mg/dl) with a high LDL, a statin is used first to lower the LDL to target level, then either gemfibrozil or niacin is added. The patient is carefully instructed in either case to alert the clinic if muscle pain develops. CK levels are not monitored routinely, but one 55
4 is obtained if there is a history supporting development of myopathy. CONCLUSION We recommend that all health care providers prescribing statins recognize that this class of medication has numerous drug-drug interactions. When statins are combined with gemfibrozil, there is an increased risk of myopathy or rhabdomyolysis. Caution is especially indicated for patients with associated conditions including renal insufficiency that place them at increased risk. Theoretically, the risk of myopathy with combination therapy may vary by compound within the statin class, but more studies are needed to assess the actual risk of each compound. If combination therapy is needed, patients should closely monitor and report muscle pain or weakness, and clinicians should have a low threshold to obtain CPK levels in symptomatic patients. Clinicians should also consider discontinuing statins or gemfibrozil temporarily when patients are at increased risk of myopathy, or when an interacting medication is needed for a short period of time. REFERENCES 1. National Cholesterol Education Panel Adult Treatment Panel III. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285: Knopp RH. Drug treatment of lipid disorders. New Eng J Med. 1999;341: Pierce L, Wysowski D, Gross T. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA. 1990;264: Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther. 1998;63: Micromedex. Copyright MICROMEDEX Thomson Healthcare MICROMEDEX(R) Healthcare Series Vol Physicians Desk Reference. Montvale NJ, Medical Economics Company, Inc., 2002, page Boccuzzi S, Bocanegra T, Walker J. Long-term safety and efficacy profile of simvastatin. Am J Card. 1991;68: Dujovne CA, Chremos AN, Pool JL, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. IV. Additional perspectives on the tolerability of lovastatin. Am J Med. 1991:91(Suppl 1B): Gaist D, Rodriguez LAG, Huerta C, et al. Lipid-lowering drugs and the risk of myopathy: a population-based followup study. Epidemiology. 2001;12: Shepherd J. Fibrates and statins in the treatment of hyperlipidemia: an appraisal of their efficacy and safety. Euro Heart J. 1995;16: Guyton JR, Dujovne CA, Illingworth DR. Dual metabolism of cerivastatin-clarifications. Am J Card. 1999;84: Sekowski I, Samuel P. Clofibrate-induced acute muscular syndrome. Am J Cardiol. 1972;30: Murdock D, Murdock A, Murdock R, et al. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders. Am Heart J. 1999;138: Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Card. 1997;80: Tolbert JA. Reply (letter). N Engl J Med. 1988;318: Farnier A, Dejager S. Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group. Am J Cardio. 2000;85: Stein EA, Davidson MH, Dujovne CA, et al. The efficacy and tolerability of low dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia: a prospective trial. J Cardiovasc Pharmacol Ther. 1996;1: Kashyap ML, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol. 2002;89: Bays HE, Dujovne CA. Drug interactions of lipid-altering drugs. Drug Safety. 1998;19: Tal A, Rajeshawari M, Isley W. Rhabdomyolysis associated with simvastatin-gemfibrozil therapy. Southern Med J. 1997;90: Pogson G, Kindred L, Carper B. Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy. Am J Card. 1999;83: Duell PB, Connor WE, Illingworth DR: Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am J Cardiol. 1998;81: Ahmad S. Lovastatin-induced myopathy in a hypothyroid patient. J Fam Pract. 1995;41: Physicians Desk Reference. Montvale NJ, Medical Economics Company, Inc., 2002, page Kayikcioglu M, Ozerkan F, Soydan I. Effectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemia. Am J Card. 1999;83:
5
RISK FACTORS AND DRUG TO STATIN-INDUCED MYOPATHY
RISK FACTORS AND DRUG INTERACTION PREDISPOSING TO STATIN-INDUCED MYOPATHY Assist. Prof. Dr. Verawan Uchaipichat Clinical Pharmacy Department Khon Kaen University Advanced Pharmacotherapy 2012 Updated d
More informationFrequency of Simvastatin Prescriptions With Potentially Interacting Medications in a Veterans Affairs Health Care System
ORIGINAL RESEARCH Frequency of Simvastatin Prescriptions With Potentially Interacting Medications in a Veterans Affairs Health Care System JERILYN B. PETROPOULOS, BSPharm, PharmD, BCPS, and CRISTINA E.
More informationTo understand the formulary process from the hospital perspective
Formulary Process Michael A. Militello, Pharm.D. Cleveland Clinic Cleveland Clinic 2011 Goal and Objectives To understand the formulary process from the hospital perspective p To list the various panels
More informationRHABDOMYOLYSIS AFTER ADDITION OF DIGITOXIN TO CHRONIC SIMVASTATIN AND AMIODARONE THERAPY
RHABDOMYOLYSIS AFTER ADDITION OF DIGITOXIN TO CHRONIC SIMVASTATIN AND AMIODARONE THERAPY H Nägele (1)*, S.Behrens (1), S. Hashagen (1), M Azizi (2) 1) St. Adolfstift, Medical Clinic, Reinbek, Germany (Director:
More informationAntihyperlipidemic drugs
Antihyperlipidemic drugs The clinically important lipoproteins are LDL low density lipoprotein, VLDL very low density lipoprotein, HDL high density lipoprotein. Hyperlipidemia may caused 1. by individual
More informationA mong the 20 leading prescription
Safety and Statins: Pharmacologic and Clinical Perspectives Michael B. Bottorff, PharmD A mong the 20 leading prescription drugs in the United States, 3 agents atorvastatin (Lipitor), simvastatin (Zocor),
More informationFORTH VALLEY. LIPID LOWERING GUIDELINE v5 2016
FORTH VALLEY LIPID LOWERING GUIDELINE v5 2016 This guideline applies to people over 16 years of age. This guideline is not intended to serve as a standard of medical care or be applicable in every situation.
More informationMOLINA HEALTHCARE OF CALIFORNIA
MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel
More informationRoyal Wolverhampton Hospital Adult Lipid Lowering Therapy Guidelines Lipid Lowering Therapy for the Prevention of Cardiovascular Disease
Royal Wolverhampton Hospital Adult Lipid Lowering Therapy Guidelines 1 This guideline is intended to assist rational and cost-effective prescribing of lipid regulating medications across both primary and
More informationVI.2 Elements for a public summary. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology This medicine is used to lower levels of total cholesterol, LDL cholesterol ( bad cholesterol), and fatty substances called triglycerides
More informationPART III: CONSUMER INFORMATION
PART III: CONSUMER INFORMATION Pr SIMVASTATIN 5 Pr SIMVASTATIN 10 Pr SIMVASTATIN 20 Pr SIMVASTATIN 40 Pr SIMVASTATIN 80 Simvastatin Tablets, USP This leaflet is part III of a three-part Product Monograph
More informationLipids & Hypertension Update
Lipids & Hypertension Update No financial disclosures Michael W. Cullen, MD, FACC Senior Associate Consultant, Assistant Professor of Medicine Mayo Clinic Department of Cardiovascular Diseases 34 th Annual
More informationDYSLIPIDEMIA PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
DYSLIPIDEMIA PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Know normal cholesterol levels Understand what the role
More informationPIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia
PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,
More informationWho remembers Terfenadine? Once daily non-sedating anti-histamine. Drug Interactions: What is the CYP 450 system? What does the CYP 450 system do?
Drug Interactions: Things that go BOOM! Who remembers Terfenadine? Once daily non-sedating anti-histamine Amelie Hollier, DNP, FNP-BC, FAANP Advanced Practice Education Associates A strange thing happened
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationCholesterol targets and therapy Thomas C. Andrews, MD, FACC
Cholesterol targets and therapy Thomas C. Andrews, MD, FACC 2 Statins in secondary prevention Still first line therapy! First line therapy: high intensity statin Dose individualized based on baseline LDL
More informationThis is a lipid lowering drug strategy which should only be used within an overall lifestyle and clinical management strategy.
Treatment Guideline Statin Prescribing Objective These guidelines represent the views of the Gloucestershire Hospitals NHS Foundation Trust, which were arrived at after consideration of the available evidence
More informationAntihyperlipidemic Drugs
Antihyperlipidemic Drugs Hyperlipidemias. Hyperlipoproteinemias. Hyperlipemia. Hypercholestrolemia. Direct relationship with acute pancreatitis and atherosclerosis Structure Lipoprotein Particles Types
More informationACC/AHA/NHLBI Clinical Advisory on Statins
ACC/AHA/NHLBI Clinical Advisory on Statins ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins Writing Committee Members: Richard C. Pasternak, MD, FACC, FAHA; Sidney C. Smith, Jr, MD, FACC,
More informationEveness Rosuvastatin. Each tablet contains 5mg, 10mg, 20mg, or 40 mg of rosuvastatin (as calcium salt)
Eveness Rosuvastatin Composition Each tablet contains 5mg, 10mg, 20mg, or 40 mg of rosuvastatin (as calcium salt) Pharmacological properties Pharmacotherapeutic gruoup: HMG CoA reductase inhibitors Pharmacodynamic
More informationAntihyperlipidemic Drugs
Antihyperlipidemic Drugs Lipid disorders: Disorders of lipid metabolism are manifest by elevation of the plasma concentrations of the various lipid and lipoprotein fractions (total and LDL cholesterol,
More informationLipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
More informationTHE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST. Systemic Anti Cancer Treatment Protocol. Tivozanib. PROTOCOL REF: MPHATIVOUR (Version No: 1.
Systemic Anti Cancer Treatment Protocol Tivozanib PROTOCOL REF: MPHATIVOUR (Version No: 1.0) Approved for use in: Tivozanib is indicated for the first line treatment of advanced / metastatic renal cell
More information1.* Dosage. A. Adults
3-Hydroxy-3-Methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitors [Developed, November 1994; Revised, October 1996; September 1997; September 1998; October 1999; November 1999; August 2000; September
More informationnicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck
Scottish Medicines Consortium Resubmission nicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck New formulation 6 January 2006 The Scottish Medicines Consortium
More informationLecture 36 Dyslipidemia Therapeutics Barry LIPIDS:
LIPIDS: PATHOPHYSIOLOGY: TC or LDL-C = CVD HDL-C = CVD Association between TG and CVD not established o HyperTG associated with pancreatitis o Reducing TG w/ drug therapy doesn t CVD TYPES OF DYSLIPIDEMIA:
More informationStatin intolerance. Pr Franck Boccara, MD, PhD Cardiologie, INSERM UMRS938 CHU St Antoine, UPMC, Paris, France
Statin intolerance Pr Franck Boccara, MD, PhD Cardiologie, INSERM UMRS938 CHU St Antoine, UPMC, Paris, France Disclosure Statement of Financial Interest I currently have, or have had over the last two
More informationClinical Policy: Pitavastatin (Livalo), Ezetimibe/Simvastatin (Vytorin 10/10 mg) Reference Number: CP.CPA.62 Effective Date:
Clinical Policy: Pitavastatin (Livalo), Ezetimibe/Simvastatin (Vytorin 10/10 mg) Reference Number: CP.CPA.62 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See
More informationCardiovascular Risk and Dyslipidemia Management Clinician Guide SEPTEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Cardiovascular Risk and Dyslipidemia Management Clinician Guide SEPTEMBER 2017 Introduction This Clinician Guide is based on the 2017 KP National
More informationUniv.-Doz. Prof. Dr. W. Renner
Pharmacogenetics of statin-inducedinduced myopathies Wilfried Renner Medical University Graz Clinical Institute of Medical and Chemical Laboratory Diagnostics It started with a fungus 1973: Isolation of
More informationANTIHYPERLIPIDEMIA. Darmawan,dr.,M.Kes,Sp.PD
ANTIHYPERLIPIDEMIA Darmawan,dr.,M.Kes,Sp.PD Plasma lipids consist mostly of lipoproteins Spherical complexes of lipids and specific proteins (apolipoproteins). The clinically important lipoproteins, listed
More informationORIGINAL INVESTIGATION. Screening for Statin-Related Toxicity. The Yield of Transaminase and Creatine Kinase Measurements in a Primary Care Setting
ORIGINAL INVESTIGATION Screening for Statin-Related Toxicity The Yield of Transaminase and Creatine Kinase Measurements in a Primary Care Setting C. Christopher Smith, MD; Lana I. Bernstein, MD; Roger
More informationJoshua Shepherd PA-C, MMS, MT (ASCP)
Joshua Shepherd PA-C, MMS, MT (ASCP) None What is Cholesterol? Why cholesterol is it important? Review the National Cholesterol Education Programs guidelines (NCEP-ATPIII) Discuss New guidelines from the
More informationClinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network
pharmacoepidemiology and drug safety 2012; 21: 494 506 Published online 16 March 2012 in Wiley Online Library (wileyonlinelibrary.com).3199 ORIGINAL REPORT Clinical importance of the drug interaction between
More informationObjectives. Having completed the learning activities, the participant will be able to: Dyslipidemia: The latest treatment recommendations
Objectives Dyslipidemia: The latest treatment recommendations Margaret A. Fitzgerald, DNP, FNP-BC, NP-C, FAANP, CSP, FAAN, DCC President, Fitzgerald Health Education Associates, Inc. North Andover, MA
More informationRosuvastatin 5 mg, 10 mg and 20 mg Tablet
Rosuvastatin 5 mg, 10 mg and 20 mg Tablet Description is a preparation of Rosuvastatin. Rosuvastatin is a member of the drug class of statins, used in combination with exercise, diet, and weight-loss to
More informationRecommended dosing for pediatric patients (6 months to 12 years of age) 1. Dose based on lopinavir component* 1.25 ml ml
Abbott Virology 100 Abbott Park Road Abbott Park, IL 60064 KALETRA 100/25 mg tablets NDC #0074-0522-60 Dear Healthcare Provider: Introducing a new strength of KALETRA (lopinavir/ritonavir): 100/25 mg tablets
More informationPharmacology Challenges: Managing Statin Myalgia
Clinical Case: RM is a 50 year-old African American woman with a past medical history of type diabetes, dyslipidemia, hypertension and peripheral arterial disease. She had been prescribed simvastatin 80
More informationManagement of Post-transplant hyperlipidemia
Management of Post-transplant hyperlipidemia B. Gisella Carranza Leon, MD Assistant Professor of Medicine Lipid Clinic - Vanderbilt Heart and Vascular Institute Division of Diabetes, Endocrinology and
More informationROSULIP. Composition Rosulip 10 mg Each tablet contains 10 mg Rosuvastatin (as calcium).
ROSULIP Composition Rosulip 10 mg Each tablet contains 10 mg Rosuvastatin (as calcium). Tablets Rosulip 20 mg Each tablet contains 20 mg Rosuvastatin (as calcium). Action Rosuvastatin is a selective and
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationElements for a Public Summary
Rosuvastatin Stada 5 mg film-coated tablets Rosuvastatin Stada 10 mg film-coated tablets Rosuvastatin Stada 20 mg film-coated tablets Rosuvastatin Stada 40 mg film-coated tablets 25.8.2014, V1.1 PUBLIC
More informationATORIS 10, 20, 40 mg film-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER ATORIS 10, 20, 40 mg film-coated tablets ATORVASTATIN This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine,
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationAnti Hyperlipidemic Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Anti Hyperlipidemic Drugs Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Lipoproteins Macromolecular complexes in the blood that transport lipids Apolipoproteins
More informationThere is some evidence to suggest that the half-life of felbamate may be prolonged by gabapentin.
amciclovir amciclovir + Probenecid Probenecid is predicted to increase the exposure to penciclovir, the active metabolite of famciclovir, possibly resulting in increased adverse effects. Evidence is limited
More information4/24/15. AHA/ACC 2013 Guideline Key Points
Review of the ACC/AHA 2013 Guidelines Anita Ralstin, MS, CNS, CNP Next Step Health Consultant, LLC 1! Discuss the rationale for the change in lipid guidelines and how that affects the decision to implement
More informationCardiovascular Drugs and Therapies HMG CoA a REDUCTASE INHIBITORS (available in Canada)
Trade Name Dosage Forms 10 mg, 20 mg, 40 mg, 80 mg tablets Dosing Range 10-80 mg once daily 2 Dosing Based on Desired LDL Reduction 1,2,3 HMG CoA a REDUCTASE INHIBITORS (available in Canada) LIPITOR, generics
More informationJuly 2011 Medical Update Information
July 2011 Medical Update Information Simvastatin (Zocor) new FDA restrictions FDA statement June 2011 Based on the SEARCH 7 year trial in patients who were considered stable after have had a heart attack.
More informationROSUVASTATIN CORE SAFETY PROFILE
ROSUVASTATIN CORE SAFETY PROFILE EU CSP rosuvastatine NL/H/PSUR/00019/005 4.2 Posology and method of administration The recommended start dose is 5 or 10 mg orally once daily in both statin naïve or patients
More informationConflicts of interest. What's the Skinny on the Lipid Guidelines? Key Differences. Are you applying the new ACC/AHA Lipid guidelines in your practice?
Conflicts of interest What's the Skinny on the Lipid Guidelines? The presenter has no relevant conflicts of interest to disclose. Kathleen Vest, PharmD, CDE, BCACP At the end of this presentation, pharmacist
More informationRecommendations Contraindicated with VYTORIN
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VYTORIN safely and effectively. See full prescribing information for VYTORIN. VYTORIN (ezetimibe
More informationTEMSIROLIMUS in renal cell cancer
Systemic Anti Cancer Treatment Protocol TEMSIROLIMUS in renal cell cancer PROTOCOL REF: MPHARTEMS (Version No: 1.0) Approved for use in: First-line treatment of adult patients with advanced renal cell
More informationEvaluation of cases of severe statin-related transaminitis within a large health maintenance organization
The American Journal of Medicine (2005) 118, 618 624 CLINICAL RESEARCH STUDY Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization Evguenia C. Charles,
More informationsrmp Atorvastatin Medical Valley
srmp Atorvastatin Medical Valley VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology This product is indicated for the lowering of cholesterol blood levels and the prevention of
More informationPACKAGE INSERT TEMPLATE FOR ATORVASTATIN TABLET. Brand or Product Name [Product name] Tablet 80mg
PACKAGE INSERT TEMPLATE FOR ATORVASTATIN TABLET Brand or Product Name [Product name] Tablet 10mg [Product name] Tablet 20mg [Product name] Tablet 40mg [Product name] Tablet 80mg Name and Strength of Active
More informationFibrates. Spotlight on. Fibric acid derivatives (fibrates) have been used. When should I prescribe fibrates? In this article: Andrew s visit
Focus on CME at the University of Alberta Spotlight on By T. K. Lee, MSc (Exp. Medicine), MB, BS, MRCP(UK), ABIM, FRCPC As presented at the Drug Update & Practical Therapeutics Course, November 8, 2002.
More informationCholesterol. Medicines To Help You
Medicines To Help You Cholesterol Use this guide to help you talk to your doctor, pharmacist, or nurse about your cholesterol medicines. The guide lists all of the FDA-approved products now available to
More informationPharmacologic Characteristics of Statins
Clin. Cardiol. Vol. 26 (Suppl. III), III-32 III-38 (2003) Pharmacologic Characteristics of Statins JAMES M. MCKENNEY, PHARM.D. National Clinical Research, Inc., and School of Pharmacy, Virginia Commonwealth
More informationManaging myopathy in the statin-intolerant patient
Managing myopathy in the statin-intolerant patient Author Hamilton-Craig, Ian Published 2012 Journal Title Medicine Today Copyright Statement 2012 Medicine Today Pty. Ltd.. Reproduced in accordance with
More informationNew ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice. Lipids. Professor Željko Reiner, MD, PhD, FRCP(Lond), FESC, FACC
New ES Guidelines on ardiovascular Disease Prevention in linical Practice Lipids Professor Željko Reiner, MD, PhD, FRP(Lond), FES, FA University Hospital enter Zagreb School of Medicine, University of
More informationOriginal paper. Abstract. Abdullah S. Asia 1*, Al-Mahdi A. Modar 2, Hadi M. Ali 3
Original paper Frequency Of Potential Adverse Effects Of A Semisynthetic Statin (Simvastatin) Compared To A Synthetic Statin (Atorvastatin) Used To Reduce Cardiovascular Risk For Patients In Basra 1*,
More informationAdvice on reducing the risk of statin interactions Karen Baxter MSc, MRPharmS and C Rhoda Lee PhD, MRPharmS
Advice on reducing the risk of statin interactions Karen Baxter MSc, MRPharmS and C Rhoda Lee PhD, MRPharmS VM The editors of Stockley s Drug Interactions highlight the potentially serious interactions
More information2.3 CONTACT HOURS. Managing. By Kristine Anne Scordo, PhD, RN, ACNP-BC, FAANP
2.3 CONTACT HOURS 2.3 CONTACT HOURS Managing hyperlipidemia The updated cholesterol treatment guidelines Abstract: The ACC/AHA 2013 cholesterol treatment guidelines focus on lowering the risk of heart
More informationDisclosures. How do statins work? Statin Pharmacokinetics 9/12/2013 THERAPEUTIC INTERVENTIONS FOR STATIN INTOLERANT PATIENTS
Disclosures Speakers Bureau- LipoScience Inc. THERAPEUTIC INTERVENTIONS FOR STATIN INTOLERANT PATIENTS Casey Elkins, DNP, NP-C, CLS How do statins work? Bays H, Stein EA. Expert Opin Pharmacother. 2003;4(11):1901-1938.
More informationImbalances in lipid components
Drugs for Dyslipidemia Vivien Gam, Pharm.D. 1 Dyslipidemia Imbalances in lipid components High total cholesterol High LDL cholesterol Low HDL cholesterol High triglycerides Significant risk factor for
More informationElements for a public summary
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Cardiovascular disease (CVD) is responsible for one-third of global deaths and is a leading and increasing contributor to the
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationDrug Use Criteria: 3-Hydroxy-3-Methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitors (Statins)
Texas Vendor Program Use Criteria: 3-Hydroxy-3-Methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitors (Statins) Publication History Developed November 1994. Revised March 2018; March 2017; December 2014;
More informationComparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients
Comparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients Cardiology Department, Bangkok Metropolitan Medical College and Vajira Hospital, Bangkok, Thailand Abstract
More information( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD )
005 6 69-74 40 mg/dl > 50 mg/dl) (00 mg/dl < 00 mg/dl(.6 mmol/l) 30-40% < 70 mg/dl 40 mg/dl 00 9 mg/dl fibric acid derivative niacin statin fibrate statin niacin ( ) ( Diabetes mellitus,
More informationDiabetes Complications Guideline Based Screening, Management, and Referral
Diabetes Complications Guideline Based Screening, Management, and Referral Eric L. Johnson, M.D. Associate Professor Department of Family and Community Medicine Assistant Medical Director Altru Diabetes
More informationDyslipidemia and HIV NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Dyslipidemia and HIV Heidi Crane, MD, MPH Madison Metabolic Clinic Associate Professor UW Department of Medicine Presentation prepared by: Heidi Crane, MD,
More informationSIMOVIL 10 mg SIMOVIL 20 mg SIMOVIL 40 mg
PATIENT PACKAGE INSERT IN ACCORDANCE WITH THE PHARMACISTS REGULATIONS (PREPARATIONS) 1986 This medicine can be sold under doctor's prescription only SIMOVIL 10 mg SIMOVIL 20 mg SIMOVIL 40 mg Tablets Tablets
More informationStatin differences - Are they all the same?
Statin differences - Are they all the same? LDL Cholesterol Goals and Cutpoints (2004) Risk Category LDL Goal (mg/dl) LDL (mg/dl) - Therapeutic Lifestyle Changes LDL (mg/dl) - Drug Therapy (TLC) CHD or
More informationTreatment of Cholesterol in 2018: Time to Level Up. Most Important Slide. Three Things Learned that Will be Applied
Treatment of Cholesterol in 2018: Time to Level Up 1. Most Important Slide Three Things Learned that Will be Applied 2. 3. 2013 Top Ten Points 1. Expert committee. Evidence used. 2. Four groups identified
More informationCRESTOR 10 mg, 20 mg, 40 mg Film Coated Tablets
CRESTOR 10 mg, 20 mg, 40 mg Film Coated Tablets COMPOSITION Each film coated tablet contains 10 mg, 20 mg, or 40 mg of rosuvastatin as rosuvastatin calcium. PHARMACEUTICAL FORM Film-coated tablet Round,
More informationCRESTOR 10 mg, 20 mg, 40 mg ASTRAZENECA
10-14 rosuvastatin calcium Film coated tablets Composition Each tablet contains 5 mg, 10 mg, 20 mg, or 40 mg of rosuvastatin (as calcium salt). Also contains glycerol. Pharmaceutical form Film-coated tablet.
More informationSIMVASTATIN AND EZETIMIBE IN THE DRUG PRODUCTS
SIMVASTATIN AND EZETIMIBE IN THE DRUG PRODUCTS T.V.KAMALI Ph.D. Research Scholar of Bharathiar University Coimbatore- 641 046 Dr. T. ANANDABASKARAN Assistant Professor, Department of Chemistry, Annamalai
More informationAs we mark the tenth anniversary
Statin Treatment in Diabetes Mellitus John Buse, MD, PhD, CDE As we mark the tenth anniversary of the publication of the Diabetes Control and Complications Trial and the fifth anniversary of the United
More informationHae Sun Suh, B.Pharm., Ph.D. Jason N. Doctor, Ph.D.
Podium Presentation, May 18, 2009 Comparison of Cardiovascular Event Rates in Subjects with Type II Diabetes Mellitus who Augmented from Statin Monotherapy to Statin Plus Fibrate Combination Therapy with
More informationDrug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin
Drug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin Final Report Update 5 November 2009 This report reviews information about the comparative
More informationHMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions
BRIEF COMMUNICATION HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions T. HUYNH, 1 D. CORDATO, 2 F. YANG, 5 T. CHOY, 3 K. JOHNSTONE, 1 F. BAGNALL, 1 N. HITCHENS 2 and R.
More informationCPE Session 7. Update on Clinical Practice Guidelines and Best Evidence in the Management of Hyperlipidemia and Cardiovascular Risk Reduction
CPE Session 7 Update on Clinical Practice Guidelines and Best Evidence in the Management of Hyperlipidemia and Cardiovascular Risk Reduction Saturday, April 25, 2015 ACPE UAN 0128-0000-15-027-L01-P 1.0
More informationElements for a public summary
VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology Familial hypercholesterolemia (FH) is a genetic disorder characterized by high cholesterol levels, specifically very high levels
More informationIn the Know: Canadian Guidelines for Dyslipidemia, 2003
In the Know: Canadian Guidelines for Dyslipidemia, 2003 In his reviews of Canadian dyslipidemia guidelines, Dr. Curnew explores the impact of major trials, the assessment and categories of risk, and both
More informationElements for a Public Summary
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Ezetimibe/simvastatin is used to reduce the risk of cardiovascular events in patients with coronary heart disease (CHD). CHD occurs
More informationFarmacologia di genere. Prof. Alberto Corsini Università degli Studi di Milano
Farmacologia di genere Prof. Alberto Corsini Università degli Studi di Milano Women have been less enrolled in clinical trials A gender-specific analysis usually is not included in the evaluation of results
More informationHIGHLIGHTS OF PRESCRIBING
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use simvastatin safely and effectively. See full prescribing information for simvastatin. Simvastatin
More informationWithdrawal of Cerivastatin Revealed a Flaw of Post-marketing Surveillance System in the United States
Bull. Natl. Inst. Health Sci., 123 Notes # Withdrawal of Cerivastatin Revealed a Flaw of Post-marketing Surveillance System in the United States Journal of American Medical Association (JAMA) Statin HMG
More informationPHARMACOKINETICS ABSORPTION
Ezetrol adalah obat baru yang terdaftar tahun 2003. Informasi di bawah ini merupakan informasi update tahun 2007. EZETROL Tablet Ezetimibe COMPOSITION Each tablet of EZETROL for oral administration contains
More informationElements for a Public Summary. Overview of disease epidemiology. Cardiovascular Events
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Cardiovascular Events Each year cardiovascular disease (CVD) causes 3.9 million deaths in Europe and over 1.8 million deaths in
More informationHow to use statins in patients with chronic liver disease
REVIEW CME CREDIT MARK W. RUSSO, MD Center for the Study of Hepatitis C, Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, NY IRA M. JACOBSON, MD Center for the Study
More informationTreating Hyperlipidemias in Adults. Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC
Treating Hyperlipidemias in Adults Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC Disclosures Conflicts: None Talk will address off-label
More informationPrevention of Heart Disease: The New Guidelines
Prevention of Heart Disease: The New Guidelines Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California San Francisco May 18 th 2015
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More informationTuesday, October 18 3:30 p.m. 5:30 p.m. Convention Center: Rooms 315 & 316
Ambulatory Care PRN Focus Session New Developments in Hypertension and Dyslipidemia Management Activity No. 0217-0000-11-101-L01-P (Application-Based Activity) Tuesday, October 18 3:30 p.m. 5:30 p.m. Convention
More information